Filgotinib is indicated as monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||13/10/2020|
|Rapid review completed||16/11/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of filgotinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations March 2021.